☰

cached image

Laurie E. Littlepage - Publications

Affiliations: 
Chemistry and Biochemistry University of Notre Dame, Notre Dame, IN, United States 
Area:
cancer progression and normal tissue development in the mammary gland and prostate
Website:
http://chemistry.nd.edu/faculty/detail/llittlep/
Tree Info Similar researchers PubMed Report error

44 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Charlestin V, Fulkerson D, Arias Matus CE, Walker ZT, Carthy K, Littlepage LE. Aquaporins: New players in breast cancer progression and treatment response. Frontiers in Oncology. 12: 988119. PMID 36212456 DOI: 10.3389/fonc.2022.988119  0.328
2020 Northey JJ, Barrett AS, Acerbi I, Hayward MK, Talamantes S, Dean IS, Mouw JK, Ponik SM, Lakins JN, Huang PJ, Wu J, Shi Q, Samson S, Keely PJ, Mukhtar RA, ... ... Littlepage LE, et al. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217. The Journal of Clinical Investigation. PMID 32721948 DOI: 10.1172/Jci129249  0.347
2020 Dai C, Charlestin V, Wang M, Walker ZT, Miranda-Vergara MC, Facchine BA, Wu J, Kaliney WJ, Dovichi NJ, Li J, Littlepage LE. Aquaporin-7 Regulates the Response to Cellular Stress in Breast Cancer. Cancer Research. PMID 32631905 DOI: 10.1158/0008-5472.Can-19-2269  0.422
2020 Kim B, Shin J, Wu J, Omstead DT, Kiziltepe T, Littlepage LE, Bilgicer B. Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 32276005 DOI: 10.1016/J.Jconrel.2020.04.010  0.327
2020 Littlepage LE, Ewald AJ, Alexander C, Casbon A, Lu P, Kessenbrock K, Provot S, Phillips JJ, Kouros-Mehr H, Chan M, Welm B, Lilla JN, Chou J, Lawson D, Lemieux G, et al. Zena Werb (1945–2020) Cell Stem Cell. 27: 356-358. DOI: 10.1016/J.Stem.2020.08.006  0.692
2020 Littlepage LE, Ewald AJ, Alexander C, Casbon A, Lu P, Kessenbrock K, Provot S, Phillips JJ, Kouros-Mehr H, Chan M, Welm B, Lilla JN, Chou J, Lawson D, Lemieux G, et al. Zena Werb (1945–2020) Developmental Cell. 54: 299-301. DOI: 10.1016/J.Devcel.2020.07.012  0.692
2019 Romero-Moreno R, Curtis KJ, Coughlin TR, Cristina Miranda-Vergara M, Dutta S, Natarajan A, Facchine BA, Jackson KM, Nystrom L, Li J, Kaliney W, Niebur GL, Littlepage LE. The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis. Nature Communications. 10: 4404. PMID 31562303 DOI: 10.1038/S41467-019-12108-6  0.401
2019 Ni Y, Schmidt KR, Werner BA, Koenig JK, Guldner IH, Schnepp PM, Tan X, Jiang L, Host M, Sun L, Howe EN, Wu J, Littlepage LE, Nakshatri H, Zhang S. Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer. Nature Communications. 10: 2860. PMID 31253784 DOI: 10.1038/S41467-019-10743-7  0.422
2019 Breuer EK, Fukushiro-Lopes D, Dalheim A, Burnette M, Zartman J, Kaja S, Wells C, Campo L, Curtis KJ, Romero-Moreno R, Littlepage LE, Niebur GL, Hoskins K, Nishimura MI, Gentile S. Potassium channel activity controls breast cancer metastasis by affecting β-catenin signaling. Cell Death & Disease. 10: 180. PMID 30792401 DOI: 10.1038/S41419-019-1429-0  0.422
2018 Dai C, Arceo J, Arnold J, Sreekumar A, Dovichi NJ, Li J, Littlepage LE. Metabolomics of oncogene-specific metabolic reprogramming during breast cancer. Cancer & Metabolism. 6: 5. PMID 29619217 DOI: 10.1186/S40170-018-0175-6  0.369
2018 Takai K, Drain AP, Lawson DA, Littlepage LE, Karpuj M, Kessenbrock K, Le A, Inoue K, Weaver VM, Werb Z. Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers. Genes & Development. PMID 29483153 DOI: 10.1101/Gad.301366.117  0.565
2018 Drain AP, Takai K, Lawson DA, Littlepage LE, Karpuj M, Kessenbrock K, Le A, Inoue K, Weaver VM, Werb Z. Abstract LB-055: Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive, basal-like breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-055  0.61
2018 Romero-Moreno R, Coughlin T, Curtis K, Dutta S, Niebur G, Littlepage LE. Abstract 56: CXCL5 is a master regulator of the dormancy switch to activate metastatic colonization of dormant breast cancer cells during bone metastasis Cancer Research. 78: 56-56. DOI: 10.1158/1538-7445.Am2018-56  0.413
2018 Vergara MCM, Hartland E, Jang C, McGarel M, Moreno RR, Kaliney W, Littlepage LE. Abstract 5078: Stromal MMP3 inhibits oncogenic potential during breast cancer progression Tumor Biology. DOI: 10.1158/1538-7445.Am2018-5078  0.423
2018 Dai C, Arceo J, Arnold J, Wu J, Dovichi NJ, Sreekumar A, Li J, Littlepage LE. Abstract 3475: Novel correlation-based network analysis of breast tumor metabolism identifies the glycerol channel protein Aquaporin-7 as a regulator of breast cancer metastasis Cancer Research. 78: 3475-3475. DOI: 10.1158/1538-7445.Am2018-3475  0.439
2017 Suarez CD, Wu J, Badve SS, Sparano JA, Kaliney W, Littlepage LE. The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. Oncotarget. 8: 108534-108547. PMID 29312549 DOI: 10.18632/Oncotarget.19308  0.414
2017 Sawe RT, Mining SK, Ofulla AV, Patel K, Guyah B, Chumba D, Prosperi JR, Kerper M, Shi Z, Sandoval-Cooper M, Taylor K, Badve S, Stack MS, Littlepage LE. Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya. Tropical Medicine and Health. 45: 19. PMID 28794686 DOI: 10.1186/S41182-017-0059-4  0.375
2017 Suarez CD, Wu J, Badve SS, Sparano JA, Kaliney W, Littlepage LE. The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. Oncotarget. PMID 28740005 DOI: 10.18632/oncotarget.19308  0.305
2016 Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. PMID 27669441 DOI: 10.1038/Onc.2016.353  0.415
2016 Sawe RT, Kerper M, Badve S, Li J, Sandoval-Cooper M, Xie J, Shi Z, Patel K, Chumba D, Ofulla A, Prosperi J, Taylor K, Stack MS, Mining S, Littlepage LE. Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. Bmc Cancer. 16: 204. PMID 26964534 DOI: 10.1186/S12885-016-2204-6  0.412
2016 Suarez CD, Littlepage LE. Patient-Derived Tumor Xenograft Models of Breast Cancer. Methods in Molecular Biology (Clifton, N.J.). 1406: 211-23. PMID 26820959 DOI: 10.1007/978-1-4939-3444-7_19  0.367
2016 Dai C, Littlepage L, Li J. Abstract A39: Identification and biostatistical analysis of conserved metabolic profiles in breast tumors from transgenic mouse models Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-A39  0.408
2016 Suarez C, Sparano J, Badve SS, Littlepage LE. Abstract B37: Overcoming resistance to chemotherapy using ZNF217 as a predictive marker and therapeutic target of breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B37  0.457
2016 Hartland E, Jang C, Moreno RR, McGarel M, Badve S, Littlepage L. Abstract 5106: Unexpected roles for stromal MMP3 during breast cancer Cancer Research. 76: 5106-5106. DOI: 10.1158/1538-7445.Am2016-5106  0.451
2015 Suarez C, Badve SS, Littlepage LE. Abstract B47: The role of ZNF217 in the development of breast cancer chemoresistance Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-B47  0.449
2015 Messana MJ, Littlepage LE. Abstract 1979: Regulation of the oncogene ZNF217 by localization in breast cancer Cancer Research. 75: 1979-1979. DOI: 10.1158/1538-7445.Am2015-1979  0.421
2014 Frietze S, O'Geen H, Littlepage LE, Simion C, Sweeney CA, Farnham PJ, Krig SR. Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha. Bmc Genomics. 15: 520. PMID 24962896 DOI: 10.1186/1471-2164-15-520  0.414
2014 Messana MJ, Yang C, Littlepage LE. Abstract 4252: Regulation of the oncogene ZNF217 by localization in breast cancer Cancer Research. 74: 4252-4252. DOI: 10.1158/1538-7445.Am2014-4252  0.475
2014 Shannon BD, Littlepage LE. Abstract 4212: ADAM10/Kuzbanian is upregulated during neuroendocrine prostate carcinogenesis Cancer Research. 74: 4212-4212. DOI: 10.1158/1538-7445.Am2014-4212  0.398
2014 Torrorey R, Kerper M, Hartland E, Shi Z, Prosperi J, Badve S, Stack S, Mining S, Littlepage L. Abstract 3851: Molecular profiling of aggressive breast cancer in a unique patient population from Kenya Cancer Research. 74: 3851-3851. DOI: 10.1158/1538-7445.Am2014-3851  0.442
2013 Kessenbrock K, Dijkgraaf GJ, Lawson DA, Littlepage LE, Shahi P, Pieper U, Werb Z. A role for matrix metalloproteinases in regulating mammary stem cell function via the Wnt signaling pathway. Cell Stem Cell. 13: 300-13. PMID 23871604 DOI: 10.1016/J.Stem.2013.06.005  0.493
2012 Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, et al. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discovery. 2: 638-51. PMID 22728437 DOI: 10.1158/2159-8290.Cd-12-0093  0.741
2010 Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y, Williams K, Brenot A, Gordon JI, Werb Z. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Research. 70: 2224-34. PMID 20215503 DOI: 10.1158/0008-5472.Can-09-3515  0.502
2008 Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell. 13: 141-52. PMID 18242514 DOI: 10.1016/J.Ccr.2008.01.011  0.732
2008 Adler AS, Littlepage LE, Lin M, Kawahara TL, Wong DJ, Werb Z, Chang HY. CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. Cancer Research. 68: 506-15. PMID 18199546 DOI: 10.1158/0008-5472.Can-07-3060  0.579
2008 Littlepage LE, Egeblad M, Werb Z. The Tumor Microenvironment in Cancer Progression The Molecular Basis of Cancer. 229-239. DOI: 10.1016/B978-141603703-3.10017-2  0.521
2005 Egeblad M, Littlepage LE, Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harbor Symposia On Quantitative Biology. 70: 383-8. PMID 16869775 DOI: 10.1101/Sqb.2005.70.007  0.56
2005 Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 436: 123-7. PMID 16001073 DOI: 10.1038/Nature03688  0.537
2005 Littlepage LE, Egeblad M, Werb Z. Coevolution of cancer and stromal cellular responses. Cancer Cell. 7: 499-500. PMID 15950897 DOI: 10.1016/J.Ccr.2005.05.019  0.498
2004 Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV. Aurora A, meiosis and mitosis. Biology of the Cell / Under the Auspices of the European Cell Biology Organization. 96: 215-29. PMID 15182704 DOI: 10.1016/J.Biolcel.2003.09.008  0.709
2002 Littlepage LE, Wu H, Andresson T, Deanehan JK, Amundadottir LT, Ruderman JV. Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. Proceedings of the National Academy of Sciences of the United States of America. 99: 15440-5. PMID 12422018 DOI: 10.1073/Pnas.202606599  0.621
2002 Littlepage LE, Ruderman JV. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes & Development. 16: 2274-85. PMID 12208850 DOI: 10.1101/Gad.1007302  0.641
2001 Huang JN, Park I, Ellingson E, Littlepage LE, Pellman D. Activity of the APC(Cdh1) form of the anaphase-promoting complex persists until S phase and prevents the premature expression of Cdc20p. The Journal of Cell Biology. 154: 85-94. PMID 11448992 DOI: 10.1083/Jcb.200102007  0.317
2000 Mendez R, Hake LE, Andresson T, Littlepage LE, Ruderman JV, Richter JD. Phosphorylation of CPE binding factor by Eg2 regulates translation of c-mos mRNA. Nature. 404: 302-7. PMID 10749216 DOI: 10.1038/35005126  0.62
Show low-probability matches.